Adynxx Stock Forecast, Price & News

0.00 (0.00 %)
(As of 05/7/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume78 shs
Average Volume6,175 shs
Market Capitalization$128,326.00
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ADYX News and Ratings via Email

Sign-up to receive the latest news and ratings for Adynxx and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolOTCMKTS:ADYX
Year FoundedN/A

Sales & Book Value

Annual Sales$2.22 million





Market Cap$128,326.00
Next Earnings DateN/A
OptionableNot Optionable


See More Headlines
Adynxx logo

About Adynxx

Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.


Overall MarketRank

0.00 out of 5 stars

Medical Sector

2003rd out of 2,043 stocks

Surgical & Medical Instruments Industry

169th out of 169 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Adynxx (OTCMKTS:ADYX) Frequently Asked Questions

What stocks does MarketBeat like better than Adynxx?

Wall Street analysts have given Adynxx a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Adynxx wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Adynxx?

Adynxx saw a decrease in short interest in the month of April. As of April 15th, there was short interest totaling 200 shares, a decrease of 33.3% from the March 31st total of 300 shares. Based on an average daily trading volume, of 1,500 shares, the short-interest ratio is currently 0.1 days.
View Adynxx's Short Interest

Who are Adynxx's key executives?

Adynxx's management team includes the following people:
  • Mr. Richard Orr, Pres, CEO, Principal Financial Officer & Director (Age 60, Pay $473.59k)
  • Dr. Julien Mamet Ph.D., Founder, Chief Scientific Officer & Director (Age 45, Pay $378.47k)
  • Mr. William Martin, Exec. VP of Corp. Devel. & Operations
  • Ms. Dina Gonzalez, Principal Accounting Officer & Sr. VP of Fin.
  • Ms. Kimberley Hebert, Sr. Director of Clinical Operations

Who are some of Adynxx's key competitors?

What other stocks do shareholders of Adynxx own?

What is Adynxx's stock symbol?

Adynxx trades on the OTCMKTS under the ticker symbol "ADYX."

How do I buy shares of Adynxx?

Shares of ADYX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adynxx's stock price today?

One share of ADYX stock can currently be purchased for approximately $0.15.

How much money does Adynxx make?

Adynxx has a market capitalization of $128,326.00 and generates $2.22 million in revenue each year.

How many employees does Adynxx have?

Adynxx employs 6 workers across the globe.

What is Adynxx's official website?

The official website for Adynxx is www.adynxx.com.

Where are Adynxx's headquarters?

Adynxx is headquartered at 100 PINE STREET SUITE 500, SAN FRANCISCO CA, 94111.

How can I contact Adynxx?

Adynxx's mailing address is 100 PINE STREET SUITE 500, SAN FRANCISCO CA, 94111. The company can be reached via phone at 415-512-7740 or via email at [email protected]

This page was last updated on 5/8/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.